<DOC>
	<DOC>NCT01226966</DOC>
	<brief_summary>This observational study is conducted in Europe. The aim of this non-interventional (observational) study is to evaluate the efficacy of liraglutide (Victoza®) and to assess the conditions of use of Victoza® in daily medical practice in France.</brief_summary>
	<brief_title>Observational Study on Efficacy and Safety of Liraglutide in Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Patients diagnosed with type 2 diabetes Patients having recently started (for less than one week) or starting liraglutide (Victoza®) treatment Hypersensitivity (allergy) to liraglutide or to any of the excipients Patient is participating in a clinical trial at the inclusion Type 1 diabetes</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>